Activity of inotuzumab ozogamicin in patients with relapsed/refractory ALL
| Parameter . | N (%) . | ||
|---|---|---|---|
| Single dose, n = 49 . | Weekly, n = 40 . | Overall, n = 89 . | |
| Response | |||
| CR | 9 (18) | 8 (20) | 17 (19) |
| CRp | 16 (33) | 13 (33) | 29 (33) |
| CRi | 3 (6) | 3 (8) | 6 (7) |
| PR | 0 | 0 | 0 |
| Resistant | 18 (37) | 14 (35) | 32 (36) |
| Death <4 weeks | 3 (6) | 2 (5) | 5 (6) |
| Salvage | |||
| Salvage 1 | 13 (27) | 16 (40) | 29 (33) |
| Salvage 2+ | 36 (73) | 24 (60) | 60 (67) |
| Median survival (months) | 5.0 | 9.5 | 6.2 |
| Parameter . | N (%) . | ||
|---|---|---|---|
| Single dose, n = 49 . | Weekly, n = 40 . | Overall, n = 89 . | |
| Response | |||
| CR | 9 (18) | 8 (20) | 17 (19) |
| CRp | 16 (33) | 13 (33) | 29 (33) |
| CRi | 3 (6) | 3 (8) | 6 (7) |
| PR | 0 | 0 | 0 |
| Resistant | 18 (37) | 14 (35) | 32 (36) |
| Death <4 weeks | 3 (6) | 2 (5) | 5 (6) |
| Salvage | |||
| Salvage 1 | 13 (27) | 16 (40) | 29 (33) |
| Salvage 2+ | 36 (73) | 24 (60) | 60 (67) |
| Median survival (months) | 5.0 | 9.5 | 6.2 |
CRi, bone marrow CR; PR, partial response.